Recommended Testing in Diabetes Research

 

 Permissions and Reprints

Abstract

Diabetic disease is increasing rapidly and vast amounts of resources are spent in all countries. Thus, the screening of new compounds including plant extracts for antidiabetic effects is mandatory. In this review both simple assays [e.g., on blood glucose (after or without a glucose load), plasma insulin and extrapancreatic effects] are described as well as specific in vivo tests in diabetic animals and in vitro tests with respect to the mechanism of compounds. In total, approx. 30 selected tests are evaluated and references are given. Thus, the investigator is guided through the tests and is advised that measuring only one parameter such as glucose will not be sufficient. In the case that the financial resources are poor for the investigator, more than glucose still has to be measured. A balance is made by describing absolutely necessary investigations while concentrating on those at low cost. It has to be started with simple assays; to use one test only, however, means oversimplifying the diabetes disease; additionally antidiabetic effects may be missing. The investigator is guided through the advantages and limitations of diabetic animal models and is advised about specific in vitro tests to look at the mechanism of action. All investigators should profit from these details, not only the phytoresearchers.

References

• 1 Hauner H. Verbreitung des Diabetes mellitus in Deutschland.  Dtsch. Med. Wschr.. 1998;  123 777-82
  PubMedGoogle Scholar
• 2 Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidineodiones.  Arzneim. Forschg./Drug Res.. 1990;  40 37-42
  PubMedGoogle Scholar
• 3 Bailey C J, Turner S L, Jakeman K J, Hayes W A. Effect of Coprinus comatus on plasma glucose concentrations in mice.  Planta Med.. 1984;  50 525-6
  PubMedGoogle Scholar
• 4 Starr J I. In: Jaffe BM, Behrmann HR (eds) Methods of Hormone Radioimmunoassay; 2^nd ed. Academic press New York; 1979: pp. 613-42
  Google Scholar
• 5 Verspohl E J, Ammon H PT. Evidence for presence of insulin receptors in rat islets of Langerhans.  J. Clin. Invest.. 1980;  65 1230-7
  PubMedGoogle Scholar
• 6 Grodsky G M, Heldt A. Method for the in vitro perfusion of the pancreas. In: Larner J, Pohl SL (eds) Methods in Diabetes Research. Vol. I Laboratory Methods. Part B John Wiley & Sons New York; 1984: 137-46
  Google Scholar
• 7 Chick W L, Warren S, Chute R N, Like A A, Lauris V, Kitchen K C. A transplantable insulinoma in the rat.  PNAS. 1977;  74 628-32
  PubMedGoogle Scholar
• 8 Kraegen E W, James D E, Jenkins A B, Chisholm D J. Dose-response curves for in vivo sensitivity in individual tissues in rats.  Am. J. Physiol.. 1985;  11 E353-62
  PubMedGoogle Scholar
• 9 Like A A, Rossini A A. Streptozotocin-induced pancreatic insulitis: A new model of diabetes mellitus.  Science. 1976;  133 415-7
  PubMedGoogle Scholar
• 10 Frerichs H, Creutzfeldt W. Diabetes durch Beta-Zytotoxine. In: Pfeiffer EF (ed.) Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Vol. I, Lehmanns Verlag München; 1968: pp. 811-40
  Google Scholar
• 11 Goto Y, Suzuki K, Ono T, Sasaki M, Toyota T. Development of diabetes in the non-obese NIDDM rat (GK rat).  Adv. Exp. Med. Biol.. 1988;  246 29-31
  PubMedGoogle Scholar
• 12 Herberg L, Coleman D L. Laboratory animals exhibiting obesity and diabetes syndromes.  Metabolism. 1977;  26 59-99
  CrossrefPubMedGoogle Scholar
• 13 Koletsky S. Pathologic findings and laboratory data in a new strain of obese hypertensive rats.  Am. J. Pathol.. 1975;  80 129-42
  PubMedGoogle Scholar
• 14 McCaleb M L, Sredy J. Metabolic abnormalities of the hyperglycemic obese Zucker rat.  Metabolism. 1992;  41 522-5
  CrossrefPubMedGoogle Scholar
• 15 Zucker L M. Hereditary obesity in the rat associated with hyperlipidemia.  Ann. NY Acad. Sci.. 1965;  131 447-58
  PubMedGoogle Scholar
• 16 Coleman D L, Hummel K P. Studies with the mutation diabetes in the mouse.  Diabetologia. 1967;  3 238-48
  CrossrefPubMedGoogle Scholar
• 17 Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.  Diabetes. 1988;  37 1549-58
  PubMedGoogle Scholar
• 18 Shafir E. Animal models of non-insulin dependent diabetes.  Diabetes/Metab. Rev.. 1992;  8 179-208
  PubMedGoogle Scholar
• 19 Nakhooda A F, Like A A, Chappel C I, Wie C N, Marliss E B. The spontaneous diabetic Wistar rat (the “BB” rat). Studies prior to and during development of the overt syndrome.  Diabetologia. 1978;  14 199-207
  CrossrefPubMedGoogle Scholar
• 20 Tochino Y. Breeding and characteristics of a spontaneously diabetic non obese strain (NOD mouse) of mice. In: Shafrir E, Renold AE (eds) Lessons from Animal Diabetes;. John Libbey London; 1984: pp. 93-8
  Google Scholar
• 21 Lenzen S, Tiedge M, Elsner M, Lortz S, Weiss H, Jörns A, Klöppel G, Wedekind D, Prokop C-M, Hedrich H J. The LEW.1AR1/Ztm-iddm rat: a new model of spontaneous insulin-dependent diabetes mellitus.  Diabetologia. 2001;  44 1189-96
  CrossrefPubMedGoogle Scholar
• 22 Marquie G, Duhault J, Jacotot B. Diabetes mellitus in sand rats (Psammomys obesus). Metabolic pattern during development of the diabetic syndrome.  Diabetes. 1984;  33 438-43
  PubMedGoogle Scholar
• 23 Pictet R, Orci L, Gonet A E, Rouiller Ch, Renold A E. Ultrastructural studies of the hyperplastic islets of Langerhans of spiny mice (Acomys cahirnus).  Diabetologia. 1967;  3 188-211
  CrossrefPubMedGoogle Scholar
• 24 Wise P H, Wier B J, Hime J M, Forrest E. The diabetic syndrome in the Tuco-Tuco (Ctenomis talarum).  Diabetologia. 1972;  8 165-72
  CrossrefPubMedGoogle Scholar
• 25 Foley J E, Gliemann J. Accumulation of 2-deoxyglucose against its concentration gradient in rat adipocytes.  Biochim. Biophys. Acta. 1981;  648 100-6
  PubMedGoogle Scholar
• 26 Garvey W T, Hardin D, Juhaszova M, Dominguez J H. Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy.  Am. J. Physiol.. 1993;  264 H837-44
  PubMedGoogle Scholar
• 27 Marette A, Bukowiecki L J. Stimulation of glucose transport by insulin and norepinephrine in isolated rat brown adipocytes.  Am. J. Physiol. . 1989;  257 C714-21
  PubMedGoogle Scholar
• 28 Basi N S, Thomaskutti K G, Pointer R H. Regulation of glucose transport in isolated adipocytes by levomisole.  Can J Physiol Pharmacol. 1992;  70 1190-4
  PubMedGoogle Scholar
• 29 Prip-Buus C, Bouthillier-Voisin A C, Kohl C, Demaugre F, Girard J, Pegorier J P. Evidence for an impaired long-chain fatty acid oxidation and ketogenesis in Fao hepatoma cells.  Eur. J. Biochem.. 1992;  209 291-8
  CrossrefPubMedGoogle Scholar
• 30 Busshardt E, Gerok W, Haussinger D. Regulation of hepatic parenchymal and non-parenchymal cell function by the diadenine nucleotides Ap3A and Ap4A.  Biochim. Biophys. A.. 1989;  1010 151-9
  PubMedGoogle Scholar
• 31 Smith R L, Lawrence J C. Insulin action in denervated rat hemidiaphragm.  J. Biol. Chem.. 1984;  259 2201-7
  PubMedGoogle Scholar
• 32 Oron Y, Larner J. A modified rapid filtration assay of glycogen synthase.  Anal. Biochem.. 1979;  94 409-10
  CrossrefPubMedGoogle Scholar
• 33 Mühlbacher C, Karnieli E, Schaff P, Obermaier B, Mushack J, Rattenhuber E, Häring H U. Phorbol esters initiate in rat fat cells the full effect of insulin on glucose-carrier translocation, but not on 3-O-methylglucose transport activity.  Biochem. J.. 1989;  249 865-70
  PubMedGoogle Scholar
• 34 Brozinick J T, Etgen G J. The effects of muscle contraction and insulin on glucose transporter translocation in rat skeletal muscle.  Biochem. J.. 1994;  297 539-45
  PubMedGoogle Scholar
• 35 Müller G, Wied S. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro .  Diabetes. 1993;  42 1852-67
  PubMedGoogle Scholar
• 36 Vila M DC, Milligan G, Standaert M L, Farese R V. Insulin activates glycerol-3-phosphate-acyltransferase (de novo phosphatidic acid synthesis) through a phospholipid-derived mediator. Apparent involvement of G_iα and activation of a phospholipase C.  Biochem.. 1990;  29 8735-40
  PubMedGoogle Scholar
• 37 Koch R, Weber U. Partial purification of the solubilized insulin receptor from rat liver membranes by precipitation with concanavalin A. H-S.  Z. Physiol. Chem.. 1981;  362 347-51
  PubMedGoogle Scholar
• 38 Ashcroft S JH, Ashcroft F M. The sulfonylurea receptor.  Biochim. Biophys. Acta. 1992;  1175 45-59
  PubMedGoogle Scholar
• 39 Nicki I, Nicks J L, Ashcroft S JH. The β-cell gilbenclamide receptor is an ADP-binding protein.  Biochem. J.. 1990;  268 713-8
  PubMedGoogle Scholar
• 40 Colca J R. Insulin sensitizer drugs in development for the treatment in diabetes.  Expert. Opin. Invest. Drugs. 1995;  4 27-9
  PubMedGoogle Scholar
• 41 Maeda N, Takahashi M, Funahashi T, Kihura S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama L, Hotta K, Nakamura T, Shinomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.  Diabetes. 2001;  50 2094-9
  CrossrefPubMedGoogle Scholar
• 42 Matsuo T, Odaka H, Ikeda H. Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes.  Am. J. Clin. Nutr.. 1992;  55: Suppl 1 314S-317S
  PubMedGoogle Scholar
• 43 Madar Z, Omusky Z. Inhibition of intestinal α-glucosidase activity and postprandial hyperglycemia by α-glucosidase inhibitors in fa/fa rats.  Nutr. Res.. 1991;  11 1035-46
  PubMedGoogle Scholar
• 44 Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikawa R, Hatanaka I, Shigeta Y. Effects of a new aldose reductase inhibitor on various tissues in vitro .  J. Pharmacol. Exp. Ther.. 1984;  229 226-30
  PubMedGoogle Scholar
• 45 British Pharmacopoeia. 1988 Vol II
• 46 Verspohl E J, Roth R A, Vigneri R, Goldfine I D. Dual regulation of glycogen metaoblism by insulin and IGF-I in human hepatoma cells (HEP-G2): Analysis with an antireceptor monoclonal antibody.  J. Clin. Investig.. 1984;  74 1436-43
  PubMedGoogle Scholar
• 47 Geisen K. Special pharmacology of the new sulfonylurea glimepiride.  Arzneim. Forschg./Drug Res.. 1988;  38 1120-30
  PubMedGoogle Scholar
• 48 Wieland O. Glycerin UV-Methode. In: Bergmeyer HU (ed) Methoden der enzymatischen Analyse. Verlag Chemie Weinheim; 1974: pp. 1448-53
  Google Scholar
• 49 Zhang Zhang B, Salituro G, Szalkowski D, Li Z, Zhang Y, Royo I, Vilella D, Diez M T, Pelaez F, Ruby C, Kendall R L, Mao X, Griffin P, Calaycay J, Zierath J R, Heck J V, Smith R G, Moller D E. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice.  Science. 1999;  284 974-7
  CrossrefPubMedGoogle Scholar

General Literature/Reviews:

Joost H-G, Herberg L. Krankheitsmodelle in der Arzneimittelforschung (Vorträge vor der Paul-Martini-Stiftung). Arzneim. Forschg./Drug Research Suppl. 1998

McNeill JH. Experimental Models of diabetes. CRC Press, LLC, 1999

Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikkawa R, Hatanaka I, Shigeta Y. Effects of a new aldose reductase inhibitor on various tissues in vitro. J. Pharmacol. Exp. Ther. 1984; 229: 226 - 30

Vogel HG, Vogel WH. Drug Discovery and Evaluation. Springer Verlag, Berlin, Heidelberg, New York, pp. 535 - 97

E. J. Verspohl

Dept. of Pharmacology

Institute of Pharmaceutical and Medicinal Chemistry

Hittorfstr. 58 - 62

48149 Münster

Germany

Phone: +49-251-8333339

Fax: +49-251-8332144